Financials
Financial year 2025
DE RUYCK PHARMA from Deinze, company number BE0818535488, closed financial year 2025 with a result of € 48,219 after tax. For that financial year DE RUYCK PHARMA recorded a gross margin of € 199,257 and equity of € 306,908. Compared with financial year 2024, the result moved from € 50,055 to € 48,219. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on October 29, 2025.
€ 306,908
▲ 2% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 48,219
▼ 4% vs 2024
Profit after tax over the fiscal year.
€ 65,417
▼ 21% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 41,511 paid out
86 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
0.2
Average over the fiscal year, from the social balance sheet.
€ 10,408
▲ 112% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 38,491
▲ 59% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 1 million
▼ 9% vs 2024
€ 78,939 is repaid this year. At this pace the long-term loan is gone in ≈ 13 years.
€ 135,781
▼ 21% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 7,349
▼ 32% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 249,072 | € 249,852 | € 178,233 | € 199,257 | ▲ 12% |
| Profit after taxes | € 50,470 | € 55,070 | € 50,055 | € 48,219 | ▼ 4% |
| Equity | € 243,708 | € 250,144 | € 300,199 | € 306,908 | ▲ 2% |
| Total debts | € 1,642,156 | € 1,393,059 | € 1,300,650 | € 1,164,355 | ▼ 10% |
| Cash | € 164,944 | € 114,345 | € 82,605 | € 65,417 | ▼ 21% |
| Land & buildings | € 1,157,388 | € 1,122,000 | € 1,094,641 | € 1,047,817 | ▼ 4% |
| Retained profit | € 225,108 | € 231,544 | € 281,599 | € 288,308 | ▲ 2% |
| Dividend | € 0 | € 48,633 | € 0 | € 41,511 | |
| Bank debt | € 1,249,579 | € 1,289,530 | € 1,117,220 | € 1,018,738 | ▼ 9% |
| Balance sheet total | € 1,885,863 | € 1,643,203 | € 1,600,849 | € 1,471,263 | ▼ 8% |
| Employees (FTE) | 1 | 0.8 | - | 0.2 |
Key figures of DE RUYCK PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 October 2026.
What happened to DE RUYCK PHARMA?
What happened at DE RUYCK PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 48,219 (▼ 4% vs 2024). Source: NBB ↗
- New establishment in Knokke-Heist. KBO
- Start of the company according to the CBE. KBO
- New establishment in Deinze. KBO
In short
From € 50,470 profit in 2022 to € 48,219 profit in 2025.
Paid € 87,396 in corporate taxes since 2022.
Best year ever: 2023, with € 55,070 profit.
On average € 249,100 of value added per employee in 2022.
A new publication or filing at DE RUYCK PHARMA? We notify you, reason included.
Follow DE RUYCK PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind DE RUYCK PHARMA are Lien Van Hauwermeiren and Bertolt De Ruyck.
Directors
According to the 2025 annual accounts
Lien Van Hauwermeiren
Director
Bertolt De Ruyck
Director
Establishments
Establishment units
Physical locations of this company
Aarseleweg 2
9800 Deinze
Van Bunnenlaan 29
8300 Knokke-Heist
Active since 20 September 2016
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0818.535.488
- VAT number
- BE 0818.535.488
- Registered office
- Aarseleweg 2, 9800 Deinze
- Names & denominations
- DE RUYCK PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 15 September 2009
- Peppol
- Active · Active since 13 Feb 2024
- Activities · NACE
Detailhandel in farmaceutische producten
Groothandel in elektrische huishoudelijke apparaten en audio- en videoapparatuur
Verhuur en lease van televisietoestellen en andere audio- en videoapparatuur
Activiteiten op het gebied van computerconsultancy en beheer van computerfaciliteiten
Computerconsultancy-activiteiten